1. Turner RB, Felton A, Kosak K, Kelsey DK, Meschievitz CK. Prevention of experimental coronavirus colds with intranasal -2b Interferon. Journal of Infectious Diseases 1986; 154 (3): 443‑447. https://doi.org/10.1093/infdis/154.3.443
2. Higgins PG, Phillpotts RJ, Scott GM, Wallace J, Bernhardt LL, Tyrrell DAJ. Intranasal interferon as protection against experimental respiratory coronavirus infection in volunteers. Antimicrob Agents Chemother 1983; 24:713-5.
3. Cummins, J.M.; Beilharz, M.W.; Krakowka, S. Oral use of Interferon. J. Interferon Cytokine Res. 1999, 19, 853–857.
4. Ahmad Zedan, Ashley D. Winters, Wei Yu, Shuangyan Wang, Ashley Takeshita, Qizhi Gong. Antiviral functions of type I and type III interferons in the olfactory epithelium. Research Square. DOI: 10.21203/rs.3.rs-36665/v1.
5. Nodarse-Cuni H, Lopez-Saura P. Cuban interferon alpha-2b. Thirty years as an effective and safe drug. Biotecnologia Aplicada 34(1):1211-17.
6. Ricardo Pereda, Daniel González, Hubert Blas Rivero, Juan Carlos Rivero, Albadio Pérez, Lissette Del Rosario López, Natacha Mezquia, Rafael Venegas, Julio Roberto Betancourt, and Rodolfo Emilio Domínguez.Journal of Interferon & Cytokine Research.Sep 2020.438-442.http://doi.org/10.1089/jir.2020.0124.
7. Ricardo Pereda, Daniel González, Hubert Blas Rivero, Juan Carlos Rivero, Albadio Pérez, Lissette Del Rosario Lopez, Natacha Mezquia, Rafael Venegas, Julio Roberto Betancourt, Rodolfo Emilio Domínguez, and Hugo Nodarse.Journal of Interferon & Cytokine Research.Dec 2020.578-588.http://doi.org/10.1089/jir.2020.0188.
8. Abdo-Cuza A, Castellanos-Gutiérrez R, Treto-Ramirez J, Arencibia-Larin S, Gómez-Pariente T, González-Fernández T, HernándezPerera JC, Arocha-Stalella K, Verdecia-Gorrita N, Vento-Buigues L, Cordero-Vasallo Y, Rivero-Yi Y, González-Dias O, Nodarse-Cuni H, Machado-Martínez R, Blanco-González MA, Valdivia-Arencibia J, Mendez-Felipe D, Delgado-Almora E, Gutiérrez-Gutiérrez C, SuárezLópez J , Leiva-Torres JL, Rodríguez-Sotolongo A, Bejerano-Gil N. 2021. Safety and efficacy of intranasal recombinant human interferon alfa 2b as prophylaxis for COVID-19 in patients on a hemodialysis program. J Renal Endocrinol 7:e05.
9. Cañete R, León LM, Rodríguez L. An experience with Cuban biotech’s nasalferon to prevent SARS-CoV-2 infections in international travelers and their contacts [Letter]. MEDICC Rev. 2021 Apr;23(2):8. DOI: https://doi.org/10.37757/MR2021.V23.N2.1.
10. Regulación No. 45-2007. Requerimientos para la notificacion y el reporte de eventos adversos graves e inesperados en los ensayos clínicos. La Habana, Cuba. CECMED; 2007. Disponible en https://www.cecmed.cu.